No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARGX240517C200000
- 178.00
- -21.00-10.55%
15min DelayClose May 9 15:59 ET
178.00High178.00Low
178.00Open199.00Pre Close1 Volume1 Open Interest200.00Strike Price17.80KTurnover196.21%IV0.14%PremiumMay 17, 2024Expiry Date182.55Intrinsic Value100Multiplier7DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9919Delta0.0002Gamma2.09Leverage Ratio-0.1640Theta0.0422Rho2.07Eff Leverage0.0125Vega
Intraday
- 5D
- 1D
News
Express News | Argenx SE : Evercore ISI Cuts Target Price to $437 From $444
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
Buy Rating for Argenx Se Backed by Strong VYVGART Sales and Promising Pipeline Prospects
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Fading Rate Cut Hopes
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.06% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% lower in Thursday's premarket activity, as traders' hopes of
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.
Comments
it's number 4, $Amylyx Pharmaceuticals(AMLX.US$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
2
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
$argenx SE(ARGX.US$
Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF)
Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering.
Unexpectedly Strong Impact of Corticosteroids
The primary setback was the ...
Clinical Disappointment in Phase 3 Study: Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF)
Argenx's shares nosedived by 25% due to disappointing results from its Phase 3 study on efgartigimod subcutaneous (SC) for treating severe autoimmune diseases. The study aimed to address pemphigus vulgaris (PV) and pemphigus foliaceus (PF), causing skin blistering.
Unexpectedly Strong Impact of Corticosteroids
The primary setback was the ...
2
Read more
72840290 : you dont pump much do you @Nasser09
Jaguar8 72840290:
Jaguar8 72840290: Spotted huh?
NASSER09OP 72840290: I have another App